Clinical Trial Update: Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating hydroxyurea for Epstein-Barr virus-associated primary central nervous system lymphoma in patients with AIDS has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aids-related Lymphoma
• Epstein-barr Virus-associated Primary Central Nervous System Lymphoma

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Lymphoma | Phase 2 | Status: COMPLETED